Amyloid imaging results, from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

Document Type

Journal Article




Computing, Health and Science


Exercise, Biomedical & Health Science/Centre of Excellence for Alzheimer's Disease Research and Care




This article was originally published as: Rowe, C., Ellis, K., Rimajova, M. , Bourgeat, P., Pike, K., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., Price, R., Raniga, P., Robins, P., Acosta, O., Lenzo, N. , Szoeke, C., Salvado, O., Head, R., Martins, R. N., Masters, C., Ames, D., & Villemagne, V. (2010). Amyloid imaging results, from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31(8), 1275-1283. Original article published here.


The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the worldwide Alzheimer’s Disease Neuroimaging Initiative (ADNI), performed 11C-Pittsburgh Compound B (PiB) scans in 177 healthy controls (HC), 57 mild cognitive impairment (MCI) subjects, and 53 mild Alzheimer’s disease (AD) patients. High PiB binding was present in 33% of HC (49% in ApoE- 4 carriers vs 21% in noncarriers) and increased with age, most strongly in 4 carriers. 18% of HC aged 60-69 had high PiB binding rising to 65% in those over 80 years. Subjective memory complaint was only associated with elevated PiB binding in 4 carriers. There was no correlation with cognition in HC or MCI. PiB binding in AD was unrelated to age, hippocampal volume or memory. Beta-amyloid (A ) deposition seems almost inevitable with advanced age, amyloid burden is similar at all ages in AD, and secondary factors or downstream events appear to play a more direct role than total beta amyloid burden in hippocampal atrophy and cognitive decline.




Link to publisher version (DOI)